Use of antithrombotic agents during pregnancy

被引：252

作者：

Ginsberg, JS ^{[1
]}

Greer, I ^{[1
]}

Hirsh, J ^{[1
]}

机构：

[1] McMaster Univ, Med Ctr, Hamilton, ON L8N 3Z5, Canada

来源：

CHEST | 2001年 / 119卷 / 01期

关键词：

D O I：

10.1378/chest.119.1_suppl.122S

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：122S / 131S

页数：10

共 78 条

[1]

ANDERSON DR, 1991, THROMB HAEMOSTASIS, V65, P248

[2]

Arnaout M. Samir, 1998, Clinical and Experimental Obstetrics and Gynecology, V25, P101

[3] RECURRENCE OF VENOUS THROMBOEMBOLIC DISEASE AND USE OF ORAL-CONTRACEPTIVES [J].

BADARACC.MA ;

VESSEY, MP .

BRITISH MEDICAL JOURNAL, 1974, 1 (5901) :215-217

[4] CHONDRODYSPLASIA PUNCTATA - IS MATERNAL WARFARIN THERAPY A FACTOR [J].

BECKER, MH ;

GENIESER, NB ;

FINEGOLD, M ;

MIRANDA, D ;

SPACKMAN, T .

AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1975, 129 (03) :356-359

[5]

BEROYZ G, 1994, LANCET, V343, P619

[6] A pharmacokinetic study of dalteparin (Fragmin®) during late pregnancy [J].

Blombäck, M ;

Bremme, K ;

Hellgren, M ;

Lindberg, H .

BLOOD COAGULATION & FIBRINOLYSIS, 1998, 9 (04) :343-350

[7]

Blombäck M, 1998, BLOOD COAGUL FIBRIN, V9, P1

[8] Anti-activated Factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin [J].

Brennand, JE ;

Walker, ID ;

Greer, IA .

ACTA HAEMATOLOGICA, 1999, 101 (01) :53-55

[9] ESTABLISHING A THERAPEUTIC RANGE FOR HEPARIN-THERAPY [J].

BRILLEDWARDS, P ;

GINSBERG, JS ;

JOHNSTON, M ;

HIRSH, J .

ANNALS OF INTERNAL MEDICINE, 1993, 119 (02) :104-109

[10]

BRILLEDWARDS P, 2000, IN PRESS N ENGL J ME

← 1 2 3 4 5 6 7 8 →